CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company, was formed in 1983, and is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases, according to the company’s website (see here: www.CEL-SCI.com). SNNLive caught up with Geert Kersten, CEO of CEL-SCI Corporation at the Source Capital 2016 Disruptive Growth & Healthcare Conference in New York City, NY.
In this video interview, Mr. Kersten and our host discuss the following topics:
- Overview of CEL-SCI Corporation
- Discusses how the company’s technology and drug, under development, works
- Update since our last interview (click here)
- Clinical development
- Recent news
- Phase 3 study
- Mr. Kersten's background
- Goals and milestones for 2016
For more information about CEL-SCI Corporation, go to: www.CEL-SCI.com
The interview may contain forward looking statements about CEL-SCI Corporation. See CEL-SCI's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions